In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Some public health officials from Trump's first term have since flipped their stance on vaccines. Redfield, the former CDC ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

The move drew sharp criticism from medical and health experts. “Scrapping the fastest platform we have is a reckless move ...

HIV vaccines have been in development for decades, but a long-lasting one has yet to be successful. The mRNA technology offers new opportunities because mRNA produces a more potent antibody response.

Many people infected with HIV don’t develop those antibody levels, much less people exposed to the various attempted vaccines throughout the decades. But the hope is that an mRNA vaccine could ...

Moderna's mRNA tech could change the game in the decades-long effort to develop an HIV vaccine. The company said it expects to begin two vaccine trials in humans by the end of 2021.

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021; DOI: 10.1038/s41591-021 ...